Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_6109_T1A_RNA

— · C

d8e1465d-77a3-55a2-9476-fd364d90e9d8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.560
  • ANGIOGENESIS+0.510
  • MYC_TARGETS_V1+0.460
  • WNT_BETA_CATENIN_SIGNALING+0.430
  • APICAL_SURFACE+0.370
  • APICAL_JUNCTION+0.350
  • TGF_BETA_SIGNALING+0.350
  • NOTCH_SIGNALING+0.340
  • G2M_CHECKPOINT+0.330
  • COAGULATION+0.290

Top 10 suppressed

  • ADIPOGENESIS-0.340
  • PEROXISOME-0.340
  • BILE_ACID_METABOLISM-0.310
  • INTERFERON_GAMMA_RESPONSE-0.270
  • ALLOGRAFT_REJECTION-0.250
  • FATTY_ACID_METABOLISM-0.250
  • HEME_METABOLISM-0.240
  • IL6_JAK_STAT3_SIGNALING-0.210
  • INTERFERON_ALPHA_RESPONSE-0.190
  • OXIDATIVE_PHOSPHORYLATION-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR5903555
lung-landscapes@6
—cohortSQ10.818
2ERR2598171
medullo-epn-umap@date-based
fetalfetal0.806
3TCGA-60-2708-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.801
4ERR2598184
medullo-epn-umap@date-based
fetalfetal0.787
5SRR15030851
colon-landscapes@1
——0.777
6TCGA-AN-A04A-01A-21R-A034-07
breast-umap@18
—C0.773
7MBCProject_2290_T2_RNA
breast-umap@18
—E0.771
8C3N-03662
lung-landscapes@6
—cohortSQ20.760
9TCGA-A7-A13D-01A-13R-A12P-07
breast-umap@18
—E0.759
10SRR8518155
breast-umap@18
—E0.755

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 36 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.560Inavolisib— uncovered
ANGIOGENESIS0.510Remibrutinib— uncovered
MYC_TARGETS_V10.460Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.430Inavolisib— uncovered
APICAL_SURFACE0.370Temsirolimus— uncovered
APICAL_JUNCTION0.350Inavolisib— uncovered
TGF_BETA_SIGNALING0.350Inavolisib— uncovered
NOTCH_SIGNALING0.340Inavolisib— uncovered
G2M_CHECKPOINT0.330Inavolisib— uncovered
COAGULATION0.290Binimetinib— uncovered
MTORC1_SIGNALING0.290Inavolisib— uncovered
E2F_TARGETS0.270Inavolisib— uncovered
PROTEIN_SECRETION0.240Remibrutinib— uncovered
MYOGENESIS0.220Inavolisib— uncovered
GLYCOLYSIS0.210Inavolisib— uncovered
MYC_TARGETS_V20.210Idelalisib— uncovered
PANCREAS_BETA_CELLS0.200Cobimetinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.200Idelalisib— uncovered
SPERMATOGENESIS0.190Inavolisib— uncovered
HEDGEHOG_SIGNALING0.180Inavolisib— uncovered